Pfizer (PFE) Gets FDA Approval for Lyrica Caps in Neuropathic Pain Management Following Spinal Cord Injury

Article Stock Quotes (1) Comments (0)

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) approved the use of Lyrica (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury. Lyrica received a priority review designation for this new indication from the FDA. More than 100,000 patients – approximately 40 percent of the 270,000 patients with spinal cord injury in the United States - suffer from this chronic, complex pain condition. Neuropathic pain associated with spinal cord injury can be severely debilitating and may significantly hinder rehabilitation and the ability to regain function.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Pfizer (PFE) Discontinues Phase 3 Study of Inotuzumab Ozogamicin
• Acacia (ACTG). Nextgen Internet Systems Enter License
• Sanofi (SNY) Reports JAKARTA Met Primary Endpoint in Both Groups

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?